Linkage Software Co., Ltd. (688588.SH) terminates the acquisition of 100% equity of Kaimairui De.

18:17 13/03/2026

Lingzhi Software (688588.SH) announced that the company had planned to acquire 100% of the equity of Kaimairui (Suzhou) Information Technology Co., Ltd. through the issuance of shares and payment of cash, and to raise supporting funds. Since the planning of this transaction, the company has strictly followed the requirements of relevant laws and regulations and normative documents, actively communicated transaction plans, orderly promoted relevant work of this transaction, and organized intermediary institutions to conduct due diligence, audits, and evaluations of the target assets. Due to the failure of the parties to reach an agreement on the core terms of the transaction, in order to effectively safeguard the interests of the company and all shareholders, after careful study by the company's board of directors and friendly negotiations between the parties to the transaction, it has been decided to terminate this transaction.

Linkage Software Co., Ltd. (688588.SH) announced that the company had planned to acquire 100% of the equity of Kaimei Red (Suzhou) Information Technology Co., Ltd. through issuing shares and paying cash, and had raised funds for the transaction. Since planning this transaction, the company has strictly followed the requirements of relevant laws and regulations and normative documents, actively communicated the transaction plan, orderly advanced the related work of the transaction, and organized intermediary institutions to conduct due diligence, audit, and evaluation of the target assets. Due to the failure of the parties to reach a consensus on the core terms of the transaction, in order to effectively protect the interests of the company and all shareholders, the company's board of directors carefully studied the matter, and after friendly negotiations among the parties involved in the transaction, decided to terminate the transaction.

Huiyu Pharmaceutical (688553.SH): Injection Carfizomib Obtained Drug Registration Certificate.

JINXUN RESOURCE (03636) announces expected comprehensive profit of approximately RMB 300 million to RMB 330 million for the year 2025.

7ROAD (00797) announces a profitable year with an estimated net profit attributable to shareholders of approximately 37 million yuan in the year 2025.

Huiyu Pharmaceutical (688553.SH): Injection Carfizomib Obtained Drug Registration Certificate.

JINXUN RESOURCE (03636) announces expected comprehensive profit of approximately RMB 300 million to RMB 330 million for the year 2025.

7ROAD (00797) announces a profitable year with an estimated net profit attributable to shareholders of approximately 37 million yuan in the year 2025.